Mallinckrodt Reports on FDA Joint Advisory Committee Meeting for Stannsoporfin for the Treatment of Newborns at Risk of Developing Severe Jaundice
Go back to Mallinckrodt Reports on FDA Joint Advisory Committee Meeting for Stannsoporfin for the Treatment of Newborns at Risk of Developing Severe Jaundice| MALLINCKRODT PUBLIC LIMITED COMPANY (NYSE: MNK) | Delayed: 0.34 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.34 | 52 Week High | $85.83 | |||
| Open | $30.62 | 52 Week Low | $50.90 | |||
| Day High | $0.34 | P/E | 0.34 | |||
| Day Low | $0.34 | EPS | $1.00 | |||
| Volume | 84 | |||||
